A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis

NCT00287118 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

189

Enrollment

INDUSTRY

Sponsor class

Conditions

Candidates for Systemic Therapy for Psoriasis
Psoriasis

Interventions

DRUG: Efalizumab

Sponsor

Merck KGaA, Darmstadt, Germany